NCT03112525View on ClinicalTrials.gov

DAPHNE Study: Direct Anticoagulant PHarmacogeNEtic

CompletedOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

June 28, 2017

Primary Completion Date

January 7, 2021

Study Completion Date

January 7, 2021

Conditions
Anticoagulants and Bleeding Disorders
Interventions
DIAGNOSTIC_TEST

CYP3A4/5 and P-gp phenotyping

Phenotyping using a simplified version of the Geneva cocktail

GENETIC

CYP3A4/5 and P-gp genotyping

Selected CYP3A4, CYP3A5, CYP3A7 and ABCB1 single nucleotide polymorphism (SNP) determination

Trial Locations (1)

Unknown

HUG, Geneva

All Listed Sponsors
lead

University Hospital, Geneva

OTHER

NCT03112525 - DAPHNE Study: Direct Anticoagulant PHarmacogeNEtic | Biotech Hunter | Biotech Hunter